SCHEMBL12373486

SCHEMBL12373486

CCn1c(C(C)NS(=O)(=O)c2cc(Cl)ccc2Cl)cnc1Oc1ccc(C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 6/20 0.41
S1PR3 Q99500 1/20 0.39
MAPT P10636 3/20 0.38
AR P10275 1/20 0.38
NR3C1 P04150 1/20 0.37
CCR4 P51679 1/20 0.37
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RAB9A P51151 1/20 0.36
FBP1 P09467 1/20 0.36
HTR2A P28223 1/20 0.35
SLC6A4 P31645 1/20 0.35
KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12373581 0.93 S1PR1 (0.41) S1PR1S1PR3NR3C1CCR4HTR2A
SCHEMBL12373679 0.92 S1PR1 (0.42) S1PR1S1PR3KMT2AHTR2ASLC6A4
SCHEMBL12373638 0.91 LMNA (0.46) S1PR1ALDH1A1LMNAHTTL3MBTL1
SCHEMBL12373514 0.91 PGR (0.39) S1PR1S1PR3MAPTNR3C1ALDH1A1
SCHEMBL12373660 0.89 S1PR1 (0.42) S1PR1S1PR3
SCHEMBL12373628 0.89 S1PR1 (0.37) S1PR1S1PR3NR3C1ALDH1A1L3MBTL1
SCHEMBL12373547 0.89 PGR (0.40) S1PR1S1PR3NR3C1CCR4ALDH1A1
SCHEMBL12373632 0.89 S1PR1 (0.45) S1PR1ALDH1A1LMNAL3MBTL1SMN1; SMN2
SCHEMBL12373616 0.88 S1PR1 (0.42) S1PR1S1PR3MAPTALDH1A1LMNA
SCHEMBL12373541 0.88 ALDH1A1 (0.38) S1PR1S1PR3NR3C1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994204-B2 Binding inhibitor of sphingosine-1-phosphate TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-08-09 US disclosed
US-7994204-B2 Binding inhibitor of sphingosine-1-phosphate TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-08-09 US disclosed
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-07-16 US disclosed
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE S1PR1, S1PR3, S1PR2 S1PR1 1/4885S1PR3 2/4885MAPT 3475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.